To date, AT has primarily responded to surrogate measures of total tumour burden, for example changes in the serum tumour marker PSA to direct abiraterone therapy in prostate cancer, and AT in ACTOv will be based on changes in CA125. The gene discussed is MUC16; the disease is prostate carcinoma.